Cancer treatment is fast changing. With advent of molecular targeted therapy and immuno-oncology, advanced stage cancers may be transformed into chronic diseases. “Immuno-Oncology Hong Kong 2024” aims at providing an international platform for all clinical and preclinical, scientists, academia, healthcare professionals and pharmaceutical companies to share and discuss cancer immunotherapeutic strategies in Asia. This hybrid meeting focuses on topics including early drug development, biomarkers and site-specific applications and challenges in lung cancer, gastrointestinal & liver cancers. Pioneer leaders from Asia, Europe and United States will share their insightful experience and future perspective. Rapid knowledge transfer is the key to success in the era of immuno-oncology.